(NP (NP (NP Regulation/NN) (PP of/IN (NP (NP glucocorticoid/NN receptors/NNS) (PP in/IN (NP human/JJ mononuclear/JJ cells/NNS)))) :/:) (NP (NP (NP effects/NNS) (PP of/IN (NP glucocorticoid/NN treatment/NN))) ,/, (NP-COOD (NP (NP Cushing/NN 's/POS) disease/NN) and/CC (NP ketoconazole/NN)) ./.))
(S (NP-SBJ-31 (NP Glucocorticoid/NN receptors/NNS) (PRN -LRB-/-LRB- (NP GcR/NN) -RRB-/-RRB-)) (VP were/VBD (VP determined/VBN (NP *-31/-NONE-) (PP by/IN (NP (NP a/DT whole/JJ cell/NN assay/NN) (PP in/IN (NP (NP (NP human/JJ mononulear/JJ leukocytes/NNS) (PRN -LRB-/-LRB- (NP hMNL/NN) -RRB-/-RRB-)) (PP from/IN (NP-COOD (NP control/NN subjects/NNS) ,/, (NP (NP patients/NNS) (VP receiving/VBG (NP (NP glucocorticoid/NN therapy/NN) (PP for/IN (NP systemic/JJ diseases/NNS))))) and/CC (NP (NP (NP (NP Cushing/NN 's/POS) disease/NN) patients/NNS) (PP (PP-COOD (PP with/IN (NP *RNR*-32/-NONE-)) or/CC (PP without/IN (NP *RNR*-32/-NONE-))) (NP-32 ketoconazole/NN therapy/NN))))))))))) ./.)
(S (NP-SBJ Prolonged/JJ corticosteroid/NN treatment/NN) (VP resulted/VBD (PP in/IN (NP (NP down-regulation/NN) (PP of/IN (NP GcR/NN)))) ,/, (SBAR while/IN (S (NP (NP the/DT mean/NN level/NN) (PP of/IN (NP GcR/NN)) (PP in/IN (NP (NP Cushing/NN 's/POS) disease/NN))) (VP was/VBD (ADJP-PRD normal/JJ))))) ./.)
(S (PP In/IN (NP this/DT group/NN)) ,/, (ADVP however/RB) ,/, (NP-SBJ-COOD (NP receptor/NN levels/NNS) and/CC (NP morning/NN plasma/NN cortisol/NN values/NNS)) (VP showed/VBD (NP a/DT negative/JJ correlation/NN) ,/, (S (NP-SBJ */-NONE-) (VP indicating/VBG (NP a/DT subtle/JJ down-regulatory/JJ effect/NN)))) ./.)
(S (ADVP Furthermore/RB) ,/, (NP-SBJ GcR/NN) (VP were/VBD (ADJP-PRD unaltered/JJ) (SBAR-TMP after/IN (S (NP-SBJ these/DT patients/NNS) (VP received/VBD (NP ketoconazole/NN)))) ,/, (PP in/IN spite/NN of/IN (NP (NP a/DT marked/JJ reduction/NN) (PP in/IN (NP-COOD (NP morning/NN plasma/NN cortisol/NN) and/CC (NP (ADJP urinary/JJ free/JJ) cortisol/NN)))))) ./.)
(S (NP-SBJ We/PRP) (ADVP also/RB) (VP observed/VBD (SBAR that/IN (S (NP-SBJ ketoconazole/NN) (VP was/VBD (NP-PRD (NP a/DT weak/JJ competitor/NN) (PP of/IN (NP GcR/NN))) (PP in/IN (NP intact/JJ cells/NNS)) ,/, (SBAR although/IN (S (NP-SBJ it/PRP) (ADVP significantly/RB) (VP inhibited/VBD (NP -LCB-3H-RCB-/NN dexamethasone/NN binding/NN) (PP in/IN (NP (NP cytosolic/JJ preparations/NNS) (PP from/IN (NP rat/NN tissues/NNS))))))))))) ./.)
(S (NP-SBJ The/DT results/NNS) (VP suggested/VBD (SBAR that/IN (S-COOD (S (NP-SBJ-33 (NP GcR/NN) (PP in/IN (NP hMNL/NN))) (VP are/VBP (VP down-regulated/VBN (NP *-33/-NONE-) (PP by/IN (NP (NP synthetic/JJ steroids/NNS) (VP given/VBN (NP */-NONE-) (ADVP in/FW vivo/FW))))))) ,/, but/CC (S (NP-SBJ they/PRP) (VP showed/VBD (NP (ADJP very/RB mild/JJ) down-regulation/NN) (PP in/IN (NP (NP hypercortisolemic/JJ patients/NNS) (VP suffering/VBG (PP from/IN (NP (NP Cushing/NN 's/POS) disease/NN)))))))))) ./.)
(S (ADVP Finally/RB) ,/, (NP-SBJ we/PRP) (VP did/VBD not/RB (VP observed/VBN (NP (NP-COOD either/CC (NP up-regulation/NN) or/CC (NP antagonism/NN)) (PP of/IN (NP GcR/NN)) (PP by/IN (NP ketoconazole/NN treatment/NN))) ,/, (PP-TMP at/IN (NP (NP the/DT time/NN) (SBAR (WHADVP-36 that/IN) (S (NP-SBJ-37 (NP cortisol/NN levels/NNS) (PP of/IN (NP (NP patients/NNS) (PP with/IN (NP (NP Cushing/NN 's/POS) disease/NN))))) (VP were/VBD (VP reduced/VBN (NP *-37/-NONE-) (ADVP *T*-36/-NONE-))))))))) ./.)
(S (NP-SBJ This/DT) (VP indicates/VBZ (SBAR-COOD (SBAR that/IN (S (NP-SBJ (NP the/DT beneficial/JJ effects/NNS) (PP of/IN (NP ketoconazole/NN)) (PP in/IN (NP (NP Cushing/NN 's/POS) disease/NN))) (VP are/VBP (PP-PRD due/JJ (PP-COOD (PP to/TO (NP adrenal/JJ cortisol/NN suppression/NN)) and/CC (PP not/RB to/TO (NP (NP interaction/NN) (PP with/IN (NP (NP GcR/NN) (PP of/IN (NP target/NN cells/NNS))))))))))) ,/, and/CC (SBAR that/IN (S (NP-SBJ (NP the/DT process/NN) (PP of/IN (NP GcR/NN regulation/NN)) (PP in/IN (NP hMNL/NN))) (VP is/VBZ (NP-PRD (NP a/DT complex/JJ phenomenon/NN) (VP awaiting/VBG (NP further/RBR elucidation/NN)))))))) ./.)
